Effects of Influenza Immunization on Humoral and Cellular Alloreactivity in Humans

Overview

Journal Transplantation

Specialty General Surgery

Date 2010 Feb 25

PMID 20179666

Citations 25

Authors

Lara Danziger-Isakov

Leonid Cherkassky

Hanni Siegel

Mary McManamon

Kristen Kramer

Marie Budev

Deirdre Sawinski

Joshua J Augustine

Donald E Hricik

Robert Fairchild

Peter S Heeger

Emilio D Poggio

Affiliations

Soon will be listed here.

Abstract

Background: Alloreactive T cells and anti-human leukocyte antigen antibodies mediate transplant injury. Environmental exposures, including vaccinations, may activate the alloimmune repertoire leading to accelerated allograft injury. To test whether vaccination impacts human alloimmunity, we analyzed humoral and cellular immune reactivity in subjects undergoing influenza vaccination.

Methods: We serially obtained blood samples from 30 healthy subjects and 8 kidney and 9 lung transplant recipients who received influenza vaccination, and from 20 healthy unvaccinated controls. We measured cellular and humoral anti-influenza responses, anti-human leukocyte antigen antibodies, and alloreactive T-cell immunity (interferon-gamma ELISPOT) at 0, 2, 4, and 12 weeks after vaccination.

Results: Vaccination induced influenza-reactive humoral and cellular responses in control subjects and in transplant recipients. Only two of 30 vaccinated volunteers developed new alloantibodies, but none of the transplant patients. Vaccination also specifically and significantly augmented cellular alloimmunity based on reactivity to a panel of stimulators in both healthy subjects and in transplant recipients within 4 weeks of vaccination. The enhanced cellular alloresponse waned toward prevaccine levels by week 12.

Conclusion: Our findings newly demonstrate that influenza vaccination can have a significant impact on the potency of the alloimmune repertoire. Because the strength of the alloresponse influences long-term graft function, our results suggest that further investigation of alloimmune monitoring after vaccination is needed.

Citing Articles

Impact of COVID-19 pandemic on transplant laboratories: How to mitigate?.

Al Attas R, AlDhafir R, Mohammed A, AlAbduladheem D, Awaji M, AlAjlan K Heliyon. 2024; 10(4):e26419.

PMID: 38404840 PMC: 10884516. DOI: 10.1016/j.heliyon.2024.e26419.

Antibody responses after sequential vaccination with PCV13 and PPSV23 in kidney transplant recipients.

Mulling N, van de Sand L, Volk K, Aufderhorst U, van der Linden M, Horn P Infection. 2023; 51(6):1703-1716.

PMID: 37243960 PMC: 10665231. DOI: 10.1007/s15010-023-02054-3.

Heterologous Immunity of Virus-Specific T Cells Leading to Alloreactivity: Possible Implications for Solid Organ Transplantation.

Karahan G, Claas F, Heidt S Viruses. 2021; 13(12).

PMID: 34960628 PMC: 8706157. DOI: 10.3390/v13122359.

The Efficacy of COVID-19 Vaccines in Chronic Kidney Disease and Kidney Transplantation Patients: A Narrative Review.

Hou Y, Lu K, Kuo K Vaccines (Basel). 2021; 9(8).

PMID: 34452010 PMC: 8402591. DOI: 10.3390/vaccines9080885.

Positive flow cytometry crossmatch with discrepant antibody testing results following COVID-19 vaccination.

Xu Q, Sood P, Helmick D, Lomago J, Tevar A, Zeevi A Am J Transplant. 2021; 21(11):3785-3789.

PMID: 34241963 PMC: 8441686. DOI: 10.1111/ajt.16753.

References

Lopez C, Simmons R, MAUER S, Najarian J, GOOD R, Gentry S . Association of renal allograft rejection with virus infections. Am J Med. 1974; 56(3):280-9. DOI: 10.1016/0002-9343(74)90609-3. View

Heeger P . T-cell allorecognition and transplant rejection: a summary and update. Am J Transplant. 2003; 3(5):525-33. DOI: 10.1034/j.1600-6143.2003.00123.x. View

Gabriel R, Selwyn S, Brown D, Crossland J, Loughridge L, Morgan M . Virus infections and acute renal transplant rejection. Nephron. 1976; 16(4):282-6. DOI: 10.1159/000180612. View

Briggs J, Timbury M, Paton A, Bell P . Viral infection and renal transplant rejection. Br Med J. 1972; 4(5839):520-2. PMC: 1788750. DOI: 10.1136/bmj.4.5839.520. View

Avery R . Cardiac-allograft vasculopathy. N Engl J Med. 2003; 349(9):829-30. DOI: 10.1056/NEJMp038124. View

Poggio E, Clemente M, Hricik D, Heeger P . Panel of reactive T cells as a measurement of primed cellular alloimmunity in kidney transplant candidates. J Am Soc Nephrol. 2005; 17(2):564-72. DOI: 10.1681/ASN.2005030293. View

Taylor D, Neujahr D, Turka L . Heterologous immunity and homeostatic proliferation as barriers to tolerance. Curr Opin Immunol. 2004; 16(5):558-64. DOI: 10.1016/j.coi.2004.07.007. View

Valujskikh A . Memory T cells in allograft rejection. Adv Exp Med Biol. 2007; 601:247-56. DOI: 10.1007/978-0-387-72005-0_26. View

Chen L, Wang T, Zhou P, Ma L, Yin D, Shen J . TLR engagement prevents transplantation tolerance. Am J Transplant. 2006; 6(10):2282-91. DOI: 10.1111/j.1600-6143.2006.01489.x. View

10.

Avery R . Viral triggers of cardiac-allograft dysfunction. N Engl J Med. 2001; 344(20):1545-7. DOI: 10.1056/NEJM200105173442010. View

11.

Valujskikh A, Li X . Frontiers in nephrology: T cell memory as a barrier to transplant tolerance. J Am Soc Nephrol. 2007; 18(8):2252-61. DOI: 10.1681/ASN.2007020151. View

12.

White-Williams C, Brown R, Kirklin J, St Clair K, Keck S, ODonnell J . Improving clinical practice: should we give influenza vaccinations to heart transplant patients?. J Heart Lung Transplant. 2006; 25(3):320-3. DOI: 10.1016/j.healun.2005.09.015. View

13.

Vilchez R, McCurry K, Dauber J, Lacono A, Griffith B, Fung J . Influenza virus infection in adult solid organ transplant recipients. Am J Transplant. 2002; 2(3):287-91. DOI: 10.1034/j.1600-6143.2002.20315.x. View

14.

Grekas D, Alivanis P, Kiriazopoulou V, Dioudis C, Sioulis A, Derveniotis V . Influenza vaccination on renal transplant patients is safe and serologically effective. Int J Clin Pharmacol Ther Toxicol. 1993; 31(11):553-6. View

15.

Kobashigawa J, Johnson B, Moriguchi J, Kawata N, Drinkwater D, Laks H . Influenza vaccine does not cause rejection after cardiac transplantation. Transplant Proc. 1993; 25(4):2738-9. View

16.

Adams A, Pearson T, Larsen C . Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev. 2003; 196:147-60. DOI: 10.1046/j.1600-065x.2003.00082.x. View

17.

Adams A, Williams M, Jones T, Shirasugi N, Durham M, Kaech S . Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest. 2003; 111(12):1887-95. PMC: 161424. DOI: 10.1172/JCI17477. View

18.

Poggio E, Roddy M, Riley J, Clemente M, Hricik D, Starling R . Analysis of immune markers in human cardiac allograft recipients and association with coronary artery vasculopathy. J Heart Lung Transplant. 2005; 24(10):1606-13. DOI: 10.1016/j.healun.2004.12.110. View

19.

Pantenburg B, Heinzel F, Das L, Heeger P, Valujskikh A . T cells primed by Leishmania major infection cross-react with alloantigens and alter the course of allograft rejection. J Immunol. 2002; 169(7):3686-93. DOI: 10.4049/jimmunol.169.7.3686. View

20.

. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant. 2004; 4 Suppl 10:160-3. DOI: 10.1111/j.1600-6135.2004.00737.x. View